<a href="https://www.fiercebiotech.com/medtech/new-hepta-blood-test-could-predict-glp-1-response" hreflang="en">New Hepta blood test could predict GLP-1 response </a>
Hepta has developed a blood test that may predict patients' responses to GLP-1 weight loss medications like Ozempic and Wegovy, potentially moving prescribing from trial and error to biology-guided treatment. The test identifies pre-treatment biological markers in blood samples that correlate with treatment effectiveness, as demonstrated in a study involving overweight and obese patients.
The most valuable insight from this content for someone tracking healthtech and biotech is that Hepta's AI-powered liquid biopsy platform, LiquidTransformer, has demonstrated the ability to predict patient response to GLP-1 drugs like Ozempic and Wegovy through pre-treatment blood-based epigenetic markers. This advancement could significantly enhance precision medicine by enabling biology-guided treatment, moving away from the traditional trial-and-error approach. As Hepta plans additional studies and engages with drugmakers on metabolic diseases, this development could signal investment opportunities and partnerships in predictive diagnostics and personalized treatment strategies.